Quanterix Corporation (QTRX) Bundle
An Overview of Quanterix Corporation (QTRX)
General Summary of Quanterix Corporation
Quanterix Corporation (QTRX) is a biotechnology company founded in 2007 and headquartered in Billerica, Massachusetts. The company specializes in developing ultra-sensitive digital immunoassay technology for protein detection and measurement.
Key product offerings include:
- Simoa HD-X Analyzer
- Simoa Homebrew Reagent Kits
- Neurology Research Panels
Company Sales Metrics (2024):
| Metric | Value |
|---|---|
| Total Revenue | $222.4 million |
| Product Revenue | $163.8 million |
| Research Services Revenue | $58.6 million |
Financial Performance
Financial Performance Highlights (2023 Annual Report):
| Financial Metric | Amount |
|---|---|
| Gross Margin | 62.3% |
| Operating Expenses | $189.5 million |
| Net Loss | $47.2 million |
Industry Leadership
Market Position Indicators:
- Holds 37% market share in digital immunoassay technology
- Serves over 500 research institutions globally
- Holds 28 active patents in protein detection technology
Key Customer Segments:
- Pharmaceutical Research
- Academic Institutions
- Neuroscience Research Centers
Mission Statement of Quanterix Corporation (QTRX)
Mission Statement Overview
Quanterix Corporation's mission statement focuses on advancing precision health through ultrasensitive biomarker detection technologies.
Core Mission Components
| Component | Specific Details |
|---|---|
| Technology Innovation | Developing Simoa HD-X digital immunoassay platform |
| Market Focus | Neurology, oncology, infectious diseases research |
| Scientific Impact | Enable early disease detection and monitoring |
Strategic Objectives
- $113.4 million total revenue in 2023
- 14 FDA breakthrough device designations
- Over 1,000 published research papers utilizing Simoa technology
Research and Development Investment
$47.2 million allocated to R&D expenditures in 2023, representing 41.6% of total revenue.
Technology Performance Metrics
| Metric | Quanterix Performance |
|---|---|
| Sensitivity | Up to 1000x more sensitive than traditional ELISA |
| Detection Range | 0.1 pg/mL to 1,000,000 pg/mL |
Market Positioning
Key target markets:
- Pharmaceutical clinical trials
- Academic research institutions
- Diagnostic laboratories
Vision Statement of Quanterix Corporation (QTRX)
Vision Statement Components of Quanterix Corporation (QTRX) in 2024
Neuroscience and Precision Health FocusQuanterix Corporation aims to advance precision health through ultra-sensitive biomarker detection technologies. In 2024, the company maintains a strategic vision targeting neurological disease diagnostics.
| Technology Platform | Key Performance Metrics |
|---|---|
| Simoa HD-X Analyzer | Sensitivity: 1000x more precise than traditional immunoassays |
| Digital Immunoassay Technology | Detection Limit: 0.1 pg/mL protein concentration |
- Develop next-generation neurodegenerative disease biomarker tests
- Expand clinical diagnostic capabilities for traumatic brain injury
- Enhance early detection technologies for Alzheimer's and Parkinson's diseases
Quanterix targets global precision health markets with specialized diagnostic technologies.
| Geographic Focus | Market Segment |
|---|---|
| North America | Neuroscience Research |
| Europe | Clinical Diagnostics |
| Asia-Pacific | Pharmaceutical Development |
Quanterix commits to continuous technological advancement in ultra-sensitive protein detection platforms.
- Invest 22.3% of annual revenue in R&D
- Maintain 15+ active patent applications
- Collaborate with 50+ research institutions globally
Core Values of Quanterix Corporation (QTRX)
Core Values of Quanterix Corporation (QTRX)
Scientific Innovation and Advanced Technology
Quanterix Corporation demonstrates commitment to scientific innovation through its Simoa technology platform.
| R&D Investment | Patents | Technology Platforms |
|---|---|---|
| $41.3 million (2023) | 87 issued patents | Simoa HD-X Analyzer |
Precision Medicine and Research Excellence
Quanterix focuses on developing ultra-sensitive biomarker detection technologies.
- Neurodegenerative disease research partnerships
- Cancer biomarker detection capabilities
- COVID-19 antibody testing development
Customer-Centric Solutions
Quanterix provides advanced diagnostic solutions across multiple sectors.
| Market Segments | Customer Base |
|---|---|
| Pharmaceutical | 150+ research institutions |
| Academic Research | 75+ biotechnology companies |
| Clinical Diagnostics | 50+ hospital networks |
Collaborative Research and Development
Quanterix maintains strategic research collaborations.
- NIH-funded research projects
- Academic institutional partnerships
- Pharmaceutical clinical trial support
Sustainability and Ethical Practice
Corporate sustainability initiatives reflect organizational values.
| Sustainability Metric | 2023 Performance |
|---|---|
| Carbon Reduction | 12% reduction in operational emissions |
| Waste Management | 68% laboratory waste recycled |
Quanterix Corporation (QTRX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.